A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy

Jeffrey E. Cohen, Brendan P. Purcell, John W. MacArthur, Anbin Mu, Yasuhiro Shudo, Jay B. Patel, Christopher M. Brusalis, Alen Trubelja, Alexander S. Fairman, Bryan B. Edwards, Mollie S. Davis, George Hung, William Hiesinger, Pavan Atluri, Kenneth B. Margulies, Jason A. Burdick, Y. Joseph Woo

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Background-Neuregulin-1β (NRG) is a member of the epidermal growth factor family possessing a critical role in cardiomyocyte development and proliferation. Systemic administration of NRG demonstrated efficacy in cardiomyopathy animal models, leading to clinical trials using daily NRG infusions. This approach is hindered by requiring daily infusions and off-target exposure. Therefore, this study aimed to encapsulate NRG in a hydrogel to be directly delivered to the myocardium, accomplishing sustained localized NRG delivery. Methods and Results-NRG was encapsulated in hydrogel, and release over 14 days was confirmed by ELISA in vitro. Sprague-Dawley rats were used for cardiomyocyte isolation. Cells were stimulated by PBS, NRG, hydrogel, or NRGhydrogel (NRG-HG) and evaluated for proliferation. Cardiomyocytes demonstrated EdU (5-ethynyl-2'-deoxyuridine) and phosphorylated histone H3 positivity in the NRG-HG group only. For in vivo studies, 2-month-old mice (n=60) underwent left anterior descending coronary artery ligation and were randomized to the 4 treatment groups mentioned. Only NRG-HG-treated mice demonstrated phosphorylated histone H3 and Ki67 positivity along with decreased caspase-3 activity compared with all controls. NRG was detected in myocardium 6 days after injection without evidence of off-target exposure in NRG-HG animals. At 2 weeks, the NRG-HG group exhibited enhanced left ventricular ejection fraction, decreased left ventricular area, and augmented borderzone thickness. Conclusions-Targeted and sustained delivery of NRG directly to the myocardial borderzone augments cardiomyocyte mitotic activity, decreases apoptosis, and greatly enhances left ventricular function in a model of ischemic cardiomyopathy. This novel approach to NRG administration avoids off-target exposure and represents a clinically translatable strategy in myocardial regenerative therapeutics.

Original languageEnglish
Pages (from-to)619-626
Number of pages8
JournalCirculation: Heart Failure
Volume7
Issue number4
DOIs
StatePublished - 1 Jul 2014
Externally publishedYes

Keywords

  • Heart failure
  • Ischemia
  • Molecular biology
  • Muscle cells
  • Myocardial infarction

Fingerprint

Dive into the research topics of 'A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy'. Together they form a unique fingerprint.

Cite this